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We performed a ﬁrst-in-disease trial of in vivo CD28:CD80/86 costimulation blockade with abatacept for
acute graft-versus-host disease (aGVHD) prevention during unrelated-donor hematopoietic cell trans-
plantation (HCT). All patients received cyclosporine/methotrexate plus 4 doses of abatacept (10 mg/kg/dose)
on days 1, þ5, þ14, þ28 post-HCT. The feasibility of adding abatacept, its pharmacokinetics, pharmaco-
dynamics, and its impact on aGVHD, infection, relapse, and transplantation-related mortality (TRM) were
assessed. All patients received the planned abatacept doses, and no infusion reactions were noted. Compared
with a cohort of patients not receiving abatacept (the StdRx cohort), patients enrolled in the study (the ABA
cohort) demonstrated signiﬁcant inhibition of early CD4þ T cell proliferation and activation, affecting
predominantly the effector memory (Tem) subpopulation, with 7- and 10-fold fewer proliferating and acti-
vated CD4þ Tem cells, respectively, at dayþ28 in the ABA cohort compared with the StdRx cohort (P < .01).
The ABA patients demonstrated a low rate of aGVHD, despite robust immune reconstitution, with 2 of 10
patients diagnosed with grade II-IV aGVHD before day þ100, no deaths from infection, no day þ100 TRM, and
with 7 of 10 evaluable patients surviving (median follow-up, 16 months). These results suggest that cos-
timulation blockade with abatacept can signiﬁcantly affect CD4þ T cell proliferation and activation post-
transplantation, and may be an important adjunct to standard immunoprophylaxis for aGVHD in patients
undergoing unrelated-donor HCT.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION
Severe acute graft-versus-host disease (aGVHD) is an
often-fatal complication of allogeneic hematopoietic cell
transplantation (HCT). Many patients with grade III aGVHD
and most patients with grade IV aGVHD die from either
complications of the disease or its treatment [1,2]. Recipients
of T cellereplete unrelated-donor (URD) HCT are at especially
high risk for severe aGVHD despite current prophylaxis
strategies: The incidence in this setting can exceed 30%
[1,3-6], and URD HCT recipients often suffer early-onset,
steroid-resistant aGVHD, which is a major contributor to
day þ100 transplantation-related mortality (TRM). Although
T cell depletion can substantially decrease the risk of GVHD, it
is associated with delayed immune reconstitution andedgments on page 1648.
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13.09.003subsequent infectious and relapse-related death [5,7,8]. Thus,
the identiﬁcation of targeted agents that can prevent early
severe aGVHD, without relying on T cell depletion, remains
a critical unmet need in the ﬁeld.
Studies of targeting in vivo T cell costimulation blockade
to prevent aGVHD have identiﬁed multiple potentially
targetable T cell costimulation pathways [9-11], including
those through CD28eCD80/86 interactions. CD28 delivers
costimulatory signals that synergize with TCR signals to
lower the T cell activation threshold, resulting in enhanced
proliferation, survival, and cytokine secretion [12,13]. CTLA4-
Ig (ie, abatacept), a fusion construct of the binding domain of
CTLA4 (the inhibitory homolog of CD28) with an IgG1 tail,
was developed as a selective inhibitor of CD28eCD80/86
interactions [9,14,15]. Abatacept blocks the activating CD28-
mediated costimulation signals with >10-fold higher
avidity compared with the inhibitory CTLA4-mediated
signals [16,17], providing clinical efﬁcacy as an immuno-
suppressive agent. Abatacept currently has Food and Drug
Administration approval for autoimmune arthritis in patients
age >6 years. There is also considerable evidence from both
murine and nonhuman primate models documenting that
CTLA4-Ig can prevent aGVHD [18-21]. These preclinicalTransplantation.
Table 1
Patient and Transplantation Characteristics in the ABA Cohort
UPN Age, yr/sex Disease and Status HLA Matching (Mismatch) CMV Status (R/D) Preparative Regimen Graft Source
001-001 46/M AML, CR2 7/8 (C allele) þ/þ Bu/Cy PBSCs
001-002 61/F AML, CR1 7/8 (B antigen) / Flu/Mel PBSCs
001-004 74/F AML, CR2 7/8 (C antigen) þ/ Flu/Mel PBSCs
001-005 59/F MDS/AML 8/8 matched / Flu/Mel PBSCs
001-006 43/M Biphenotypic Phþ leukemia, CR1 8/8 matched þ/ TBI/Cy PBSCs
001-007 46/M ALL, CR1 7/8 (A antigen) þ/þ TBI/Cy PBSCs
001-008 39/M AML, CR1 8/8 matched þ/þ Bu/Cy PBSCs
001-009 40/M CML, extramedullary disease 7/8 (A antigen) þ/ Bu/Cy PBSCs
002-001 22/F ALL, CR3 8/8 match þ/þ TBI/Cy BM
002-002 17/M ALL, induction failure 7/8 (DRB1 antigen) þ/ TBI/Cy BM
AML indicates acute myelogeous leukemia; ALL, acute lymphoblastic leukemia; MDS, myelodysplatic syndrome; CML, chronic myelogenous leukemia; Phþ,
Philadelphia chromosome positive; PBSC, peripheral blood stem cell; BM, bone marrow; CR, complete remission.
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trial of in vivo abatacept for aGVHD prevention.METHODS
Study Design and Patients
The Abatacept for GVHD Prevention Feasibility Trial (ABA) was a single-
arm feasibility study with an accrual goal of 10 patients. ABA patients were
enrolled at the Winship Cancer Institute of Emory University and at Chil-
dren’s Healthcare of Atlanta’s Aﬂac Cancer and Blood Disorders Center. The
trial was registered at Clinical trials.gov (NCT01012492) and approved by the
Institutional Review Boards of both institutions. Eligibility criteria included
signed informed consent, age >12 years, high-risk hematologic malignancy,
a performance score >80, adequate organ function, lack of an HLA-matched
related donor, and an unrelated bone marrow or peripheral blood stem cell
donor matched at a minimum of 7 of 8 HLA alleles (HLA-A, -B, -C, and -DR;
a single antigen or allele mismatch was permitted).Treatment Protocol
ABA patients received 1 of 3 conditioning regimens: (1) TBI/Cy, total
body irradiation (TBI) 1200 cGy þ cyclophosphamide (Cy) 120 mg/kg; (2)
Bu/Cy, i.v. busulfan (Bu; targeted area under the curve, 900 to
1300 mmol*min/L for each of 16 doses) þ Cy 120 mg/kg; or (3) Flu/Mel,
ﬂudarabine (Flu) 125 mg/m2 þ melphalan (Mel) 140 mg/m2. Supportive
care and infection prophylaxis were administered according to institutional
standards.GVHD Prophylaxis
Abatacept, cyclosporine, and methotrexate were administered to all
patients. Cyclosporine (i.v. or oral) was started on day 3, with doses
adjusted to maintain an infusional or trough level of 100 to 300 ng/mL, and
continued at full dose through at least day þ100. Methotrexate was
administered at 15 mg/m2 on day þ1 and at 10 mg/m2 on days þ3, þ6,
and þ11. Abatacept was administered in normal saline (100 mL total
volume) by i.v. infusion over 30 minutes at a dose of 10 mg/kg (maximum
dose, 1000 mg) on days 1, þ5, þ14, and þ28. Administration of abatacept
was discontinued if the patient developed hypersensitivity or a serious
infection. In addition, it was held indeﬁnitely for persistent cytomegalovirus
(CMV) reactivation not responsive to antiviral medication and biopsy-
proven post-transplantation lymphoproliferative disorder (PTLD).Clinical Endpoints
The primary objective of this study was to determine the feasibility of
administering 4 abatacept doses to patients undergoing URD HCT. Patients
were also monitored for toxicity. Infusional reactions, grade 3 headaches
[22] (through dayþ42, according to the National Cancer Institute’s Common
Terminology Criteria for Adverse Events, version 4.0), grade 2 and greater
regimen-related toxicities (through day þ42, according to the Bearman
criteria) [23], all infections (through day þ100), and PTLD were captured. In
addition, any other unexpected serious adverse events were monitored.
Secondary endpoints also included the assessment of the rate of early (by
dayþ100) grade II-IV aGVHD in patients receiving abatacept, using standard
aGVHD grading criteria [24,25]. The inﬂuence of non-GVHD hepatic and
gastrointestinal diseases on organ staging was accounted for using the
approach developed by Weisdorf et al. [2]. In addition to monitoring stages
and grades of aGVHD, we also assessed the use of salvage therapy for
steroid-resistant aGVHD, rates of chronic GVHD (cGVHD), engraftment,
leukemic relapse, and survival.Pharmacokinetic Monitoring
Serum abatacept levels were measured by ELISA (Tandem Laboratories,
West Trenton, NJ). Terminal half-life estimates were determined using
WinNonlin Professional version 4.1 (Pharsight, Mountain View, CA).
Immune Monitoring
Longitudinal ﬂow cytometry analysis included the enumeration of CD3þ
T cells (CD3þ/CD20 lymphocytes), CD20þ B cells (CD3/CD20þ lympho-
cytes), natural killer (NK) cells (CD3/CD20/CD16þ [CD56þ and ], and
CD4þ [CD4þ/CD8] T cells), CD8þ (CD8þ/CD4 T cells) T cell subsets, and
CD4þ/CD25high/CD127low/FoxP3þ regulatory T cells (Tregs). Naïve T cells (Tn)
were characterized as CD45RAþ/CCR7þ; central memory (Tcm) cells, as
CD45RA/CCR7þ; effector memory (Tem) cells, as CD45RA/CCR7; and
terminally differentiated effector (Temra) cells, as CD45RAþ/CCR7. Prolif-
eration was measured by Ki-67 expression, and activation was measured by
CD38/HLA-DR dual expression. A complete description of the antibodies
used for ﬂow cytometry analysis is provided in Supplemental Table S1.
Outcomes for the ABA cohort were compared with those in 2 other
patient cohorts: For selected standard hematologic reconstitution studies
(neutrophil engraftment and day þ100 CD4þ T cell counts), results were
compared with those in a cohort of 22 patients who underwent HCT at
Emory University during the same time period as the ABA trial who also met
the eligibility and treatment criteria for ABA and who received
cyclosporine þ methotrexate as GVHD prophylaxis. For this cohort, patient
characteristics and selected transplantation outcomes are summarized in
Supplemental Table S2. During the ABA trial, it became evident that
a comparator arm for the extended immunologic reconstitution studies
performed on ABA patients would be advantageous. Thus, a separate
immune monitoring study was designed and Institutional Review Board-
approved. This trial was opened during the last 6 months of accrual to the
ABA trial and closed to accrual when the ABA trial met accrual goals.
Accordingly, a subgroup of 7 of patients (the StdRX cohort; patient charac-
teristics and transplantation outcomes described in Supplemental Tables S3
and S4) underwent detailed analysis to make comparisons of immune
reconstitution with the ABA patients. The StdRx cohort was treated with
cyclosporine þmethotrexate (no abatacept) for post-transplantation GVHD
prophylaxis.
Viral Monitoring
CMV PCR testing was performed from the second week post-
transplantation, except for 2 patients (UPN 001-005 and 002-001) who
underwent a ﬁrst measurement of CMV viral load at day þ20 post-
transplantation. Neither of these 2 patients exhibited CMV reactivation for
the length of the trial. Based on physician preference, 4 patients (UPN 001-
001, 001-002, 001-004, and 002-002) underwent CMV viral load measure-
ment before day þ14 (within the ﬁrst week post-transplantation); none of
these patients demonstrated CMV reactivation at these early time points. In
addition, Epstain-Barr virus (EBV) viral loads were measured by polymerase
chain reaction (PCR). Measurements were done every 2 weeks starting at
day þ21 and continued until either the CD4 count reached 400 cells/mL or at
1 year post-transplantation. Adenovirus in plasma or serumwasmeasured by
quantitative PCR at the Emory clinical laboratory during retrospective anal-
ysis from samples drawn on daysþ14,þ28,þ60,þ100,þ180, andþ365 post-
transplantation.
Viral Peptide Stimulation Assay
Cryopreserved peripheral blood mononuclear cells were thawed, rested
for 6 hours at 37 C and then costimulated (anti-CD49d, 6 mL/mL; BD
Biosciences, San Jose, CA) with or without a negative (DMSO) or positive
Table 2
Clinical Outcomes in the ABA Cohort
UPN Infusional
Reaction
(Y/N)
Grade 2-3
Regimen-
Related
Toxicity to
d þ42*
Neutrophil
Engraftment, d
Day þ30
Chimerism
(CD3/CD33)
Grade II-IV
aGVHD to
d þ100 (Y/N)
Grade II-IV
aGVHD
d þ101-365
(Y/N)
Mild
cGVHD
(Y/N)
Moderate
cGVHD
(Y/N)
Severe
cGVHD
(Y/N)
Febrile
Neutropeniay
Infection/PTLD
to d þ100yz
Alive (Y/N),
d Post-HCT
Relapse
(Y/N), d
Post-HCT
Follow-up, d
001-001 N Renal (grade 2) 16 100/100 N Y N N N N Bacteremiax Y N 810
001-002 N None 20 100/100 N N Y N N N None Y N 701
001-004 N Renal (grade 2)
Stomatitis
(grade 2)
11 100/100 N NA N N N N Bacteremia,
parainﬂuenzak
N; relapsed
disease, d þ121
Y, d þ98 121
001-005 N None 16 100/100 N N N Y N Y, d þ6 Rhinovirus{ Y N 534
001-006 N Stomatitis
(grade 2)
17 92/100# N N N Y N Y, d þ11 None Y N 561
001-007 N Stomatitis
(grade 2)
23 100/100 N NA N N N Y, d þ3 None N; relapsed
disease, d þ147
Y, d þ121 147
001-008 N Renal (grade 2)
Stomatitis
(grade 2)
11 100** Yyy Yzz N N Y N None Y N 489
001-009 N Renal (grade 2) 13 100/100 N N N Y N Y, d þ5 None Y N 455
002-001 N Stomatitis
(grade 2)
22 100/100 N N Y N N N None Y N 777
002-002 N Bladder (grade
2)
47 99/100 Y N N N Y N Cellulitis, BK
virus, LPDxx
N; multiorgan
failure, d þ453
N 453
NA indicates not available; LPD, lymphoproliferative disease.
* All regimen-related toxicities were determined to be unlikely to be attributable to the study drug.
y Fever and neutropenia and infections were determined to be possibly attributable to the study drug.
z The case of plasmacytic hyperplasia was determined to be possibly related to the study drug.
x Bacteremia with coagulase-negative staphylococcus on d þ8 and d þ70, requiring central venous line removal. Parainﬂuenza upper respiratory infection at d þ76.
k Bacteremia with Escherichia coli on d þ56.
{ Rhinovirus upper respiratory infection on d þ28.
# 100% CD3 donor chimerism by d þ260.
** Unfractionated bone marrow chimerism on d þ30.
yy aGVHD involving the gut and liver, diagnosed on d þ84, with a maximal grade III (gut).
zz Grade II aGVHD of the skin and liver on d þ29.
xx Perirectal cellulitis on d þ2, hemorrhagic cystitis/BK virus on d þ58, polyclonal lymphoproliferative disorder on d þ62.
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ulations for 12 hours (2 mg/mL per peptide; JPT, Acton MA) were performed,
with brefeldin A (1 mL/mL; Sigma-Aldrich) added after 2 hours. Cells were
stained using standard techniques with the following antibodies: antieCD4-
PE-Cy7, antieCD3-V450, antieCD8-Alexa Fluor 700, antieTNF-APC, and
antieIFN-g-PerCP-Cy5.5 (BD Biosciences), and anti-CD14 Pac Orange and
anti-CD20 Pac Orange (Life Technologies, Grand Island, NY).
Statistical Analysis
Statistical analyses were performed using Prism version 6 for Mac OS X
(GraphPad Software, La Jolla, CA).
RESULTS
Baseline Patient and Disease Characteristics
Eleven patients were enrolled in the ABA cohort. One
enrolled patient was subsequently discovered to be ineligible
because of an active infection, and was taken off the protocol
before HCT and excluded from all analysis. The median age of
the 10 eligible patients (Table 1) was 44.5 years (range, 17 to
74 years). Five patients had acute myelogenous leukemia or
myelodysplastic syndrome, 3 had acute lymphocytic
leukemia, 1 had acute leukemia of ambiguous lineage, and 1
had chronic myelogenous leukemia. All 10 patients under-
went URD HCT. Four donorerecipient pairs were 8/8 HLA-
matched (HLA-A, -B, -C, and -DRB1 loci), and the other 6
pairs were 7/8 HLA-matched. Five of these 6 pairs were
mismatched at the antigen level, and 1 pair was mismatched
at the allele level. Eight patients received peripheral blood
stem cell allografts, and 2 patients received bone marrow
grafts. All patients received intensive pretransplantation
conditioning as described in Methods. For conditioning, 3
patients received Bu/Cy, 4 received TBI/Cy, and 3 received
Flu/Mel.
Engraftment
As shown in Table 2 and Figure 1, neutrophil recovery
occurred in all patients. The median time to the ﬁrst of 3
consecutive days of an absolute neutrophil count of at least
500 cells/mL was 16.5 days (range, 11 to 47 days), not statis-
tically different from that in a cohort of 22 contemporaneous
controls (P ¼ .14; Wilcoxon rank-sum test). In addition, as
shown in Table 2, all patients engrafted with donor cells,
with day þ30 CD33þ chimerism of 100% and day þ30 CD3þ
chimerism of 92% to 100%. The single patient with 92% T cell
chimerism at day þ30 exhibited 100% T cell chimerism on
reexamination at day þ260.
Survival and Relapse
With a median follow-up of 475 days, 7 patients were
disease-free survivors (Table 2). Two patients who under-
went HCT with minimum residual disease (1 based on ﬂow
cytometry and 1 based on cytogenetics) suffered relapse and
died (at day þ121 and day þ147). Another patient died from
transplantation-related causes (cholestatic liver disease
thought to stem partly from GVHD, steroid myopathy, and
traumatic pancreatitis from a fall) at day þ453 post-
transplantation.
Tolerability, Feasibility, and Infectious Complications
Abatacept was well tolerated, with all patients receiving
the 4 doses as prescribed. No side effects of infusion were
observed. No patients experienced severe headache, a previ-
ously reported side effect in patients with rheumatoid
arthritis (RA) receiving chronic abatacept therapy [22]. Eight
patients developed grade 2 to 3 regimen-related toxicity,
none of which was considered likely attributable to the studydrug (Table 2). Four patients developed fever and neu-
tropenia (all considered possibly attributable to the study
drug), and 4 patients developed documented infection by
day þ100 (Table 2), with bacteremia the most common
infection, and all considered possibly attributable to the
study drug. Viral reactivation and infection were closely
monitored, given the data from solid organ transplantation
suggesting that belatacept (a higher-avidity formulation of
CTLA4-Ig compared with abatacept) can increase the risk of
EBV-related disease, especially during primary infection [26].
Figure 2 shows the results of PCR-based monitoring for CMV
and EBV. As shown in Figure 2A, 5 of 8 at-risk patients
demonstrated reactivated CMV, all of whomwere responsive
to ganciclovir. The ABA cohort had no primary CMV infection
and no CMV disease. Similarly, as shown in Figure 2B, no
patient developed high-level EBV reactivation. One patient
developed low-level EBV reactivation (peak viral load, 780
copies/mL) and was evaluated for PTLD with a positron
emission tomography scan, which was negative. Based on
physician preference, this patient was treated with 4 weekly
infusions of rituximab, and subsequently tested EBV PCR-
negative. One patient developed an EBV-positive plasmacy-
toid hyperplasia of the tongue on day 62 post-transplantation
in the absence of EBV viremia, whichwas considered possibly
attributable to the study drug. This lesion occurred while the
patient was being treated for GVHDwith corticosteroids, and
regressed (with regression conﬁrmed histologically) without
treatment or weaning off of immunosuppression. At the time
of the tongue biopsy, a positron emission tomography scan
demonstrated no other evidence of PTLD. No other patient
exhibited evidence of EBV-related disease. In addition, no
adenoviremia (or disease) occurred (data not shown). In
addition to clinical monitoring for viral reactivation, anti-
CMV immunity was also measured in CD8þ T cells isolated
from the ABA patients at 180 days post-transplantation. As
shown in Figure 1C and D, these T cells retained the ability to
produce both IFN-g and TNF in response to in vitro stimula-
tion with CMV peptides.
Pharmacokinetics and Pharmacodynamics
Pharmacokinetic parameters were evaluated in the ABA
patients by measuring both peak drug levels (measured
30 minutes after administration of abatacept) and trough
levels (measured immediately before each abatacept dose).
Figure 3A shows the composite drug exposure proﬁle and
summary data for the 10 patients enrolled on this study. As
shown, the mean peak abatacept level was 202.4 7.7 mg/mL
for doses 1 and 2 (range, 136.3 to 257.1 mg/mL) and
258.2 9.3 mg/mL for doses 3 and 4 (range,184.3 to 330.0 mg/
mL). The mean trough value (doses 2 to 4) was 45.6 2.6 mg/
mL (range, 24.5 to 77.3 mg/mL). Whereas the peak concen-
trations of abatacept in ABA patients were similar to those
seen observed in both RA patients and HCs (with average
peak values of 295 and 292 mg/mL, respectively) the average
trough concentration was higher in HCs than previously re-
ported in RA patients (24 mg/mL) [27]. This is likely related to
the higher early dosage intensity of abatacept in the ABA
trial. Whereas RA patients receive 3 abatacept doses within
the ﬁrst 30 days of treatment, ABA patients received 4 doses
within 30 days (similar to the CTLA4-Ig dose intensity used in
solid organ transplant recipients) [28]. As shown in
Figure 3A, the terminal half-life of abatacept measured in the
ABA patients was 19.5 days (range: 9.6 to 28.2 days). This
half-life was similar to that measured in patients with RA
(median, 13.1 days; range, 8 to 25 days) and in HCs (median,
Figure 1. Neutrophil engraftment. The percent of patients demonstrating
neutrophil engraftment (the ﬁrst of 3 consecutive days with an absolute
neutrophil count >500/mL) is depicted in red for ABA patients and black for the
contemporaneous control cohort.
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intensity of abatacept used in this study was higher than
used for RA patients, unlike the RA patients, ABA patients did
not receive chronic drug dosing. Their exposure to abatacept
was limited to the 4 doses, with a maximum level of
8.9 mcg/mL by þ100 days post-HCT (Figure 3).A
D
B
C
Figure 2. Viral reactivation and immune response in ABA patients. (A) CMV viral load
cytokine expression after stimulation with CMV-speciﬁc peptides. Cells were gated
CD20/CD14/CD3þ cells were identiﬁed, and CD8þ/CD4 cells were then identiﬁed. C
enumerated. (D) Summary data showing the percent of CD8þ T cells producing both IF
and StdRx (n ¼ 3) cohorts. Data are mean  SEM.Pharmacodynamic evaluation revealed reduced early
CD4þ proliferation during abatacept treatment. Previous
in vitro studies have shown that a key functional effect of
abatacept is its ability to inhibit T cell proliferation, with
a more signiﬁcant impact on CD4 subpopulations compared
with CD8 subpopulations [29]. In the present study, this
inhibition was documented in vivo in patients receiving the
drug. To the best of our knowledge, this study is the ﬁrst
demonstration of abatacept’s ability to inhibit T cell prolif-
eration in vivo in a patient population. Thus, as shown in
Figure 3B and C, measurement of CD4þ proliferation by ﬂow
cytometry (using Ki-67) at days þ14 and þ28 revealed
a marked decrease in the number of proliferating CD4þ T
cells in the ABA cohort compared with the StdRx cohort. This
decrease (to 86% on day þ14 and 83% on day þ28) was
statistically signiﬁcant (P < .05, Wilcoxon rank-sum test) at
both time points. As discussed below, the decrease in CD4þ T
cell proliferation was limited to the period of abatacept
exposure, with similar numbers of proliferating CD4þ T cells
seen at later time points post-HCT in the ABA and StdRx
cohorts.
GVHD
All ABA patients were evaluated for the rate of early (by
day þ100) aGVHD (Table 2). As summarized in the Table 2,. (B) EBV viral load. (C) Representative ﬂow cytometry analysis of intracellular
as follows: Lymphocytes were identiﬁed, and singlets were then gated. Live
D8þ/CD4/CD3þ/CD20/CD14 T cells producing both IFN-g and TNF were then
N-g and TNF. A comparison of baseline versus day þ180 in both the ABA (n ¼ 7)
D.T. Koura et al. / Biol Blood Marrow Transplant 19 (2013) 1638e1649 16432 ABA patients developed grade II-IV aGVHD before
day þ100. One patient developed grade II GVHD of the skin
and liver at day þ29 post-HCT (with an abatacept trough
level of 27.6 mg/mL at the time of GVHD diagnosis), and
a second patient developed gastrointestinal aGVHD at
day þ84 (with a maximum grade of III). At the time of GVHD
development, abatacept levels had decreased in this patient
as well, to <37 mg/mL (extrapolating from the day þ60
abatacept level). No patient developed grade IV aGVHD, and
no patient was treated with salvage therapy for steroid-
refractory aGVHD. One additional patient developed
steroid-responsive late aGVHD after dayþ100, and 2 patients
developed severe cGVHD (Table 2).Figure 3. Pharmacokinetic and pharmacodynamic analysis of abatacept
during HCT. (A) Pharmacokinetic analysis. Abatacept levels were measured by
ELISA on serum samples drawn on days 1, þ5, þ14, þ28, þ
42, þ60, þ100, þ180, þ365 post-transplantation. Data are mean  SEM
(n ¼ 10). The inset shows the average peak abatacept levels for doses 1 and 2
and for doses 3 and 4, the average trough abatacept levels and the terminal
half-life. (B) Pharmacodynamic analysis showing decreased CD4þ proliferation
in patients treated with abatacept. Representative ﬂow cytomety analysis
shows Ki-67þ staining of CD4þ T cells in StdRx cohort patients (left) and ABA
patients (right). Flow cytometry plots were ﬁrst gated on lymphocytes, and
then on CD3þ/CD14 T cells. CD4þ/CD8/CD3þ/CD14 T cells were then eval-
uated for the amount of Ki-67 expression. (C) Enumeration of Ki-67þ CD4þ T
cells was performed using BD TruCount Beads as described in Methods. Data
are mean  SEM of the Ki-67þ CD4þ T cells in ABA patients (n ¼ 10, red) and
StdRx patients (n ¼ 7, black). *P < .05; **P < .01, Wilcoxon rank-sum test.IMMUNE RECONSTITUTION AND ITS RELATIONSHIP
WITH ABATACEPT EXPOSURE
The patients in the ABA cohort underwent detailed
multiparameter ﬂow cytometric evaluation of immune
reconstitution. As shown in Figure 4A, the ABA patients (red
squares) demonstrated lymphocyte reconstitution post-HCT,
with mean lymphocyte count of 802  154 cells/mL at
day þ28 and 1053  259 cells/mL at day þ100, not statisti-
cally signiﬁcantly different from values in the StdRx cohort
(black circles). As reported in previous studies [30,31], in the
ABA patients, reconstitution of NK cells occurred rapidly
compared with that of many other lymphocyte populations.
Thus, as shown in Figure 4B and C, the relative tempo of NK
reconstitution was more rapid than that of T cell reconsti-
tution. This resulted in a transient peak in the absolute NK
cell counts at day þ28, followed by a subsequent decline
toward pretransplantation levels. The rapid recovery of NK
cells was not speciﬁc to ABA patients; it was also seen StdRx
patients (Figure 4B), although to a lesser extent. The
enhanced skewing toward early NK recovery in the ABA
patients, in combinationwith the reduced T cell proliferation
early after transplantation in these patients (Figure 4B and
C), produced a transient inversion in the percentage of T cells
versus NK cells to favor NK cells, compared with the StdRX
cohort (Figure 4D). This skew toward CD16þ NK cells was
seen in all NK subsets (CD56, CD56low, and CD56high; data
not shown).
Figure 5 shows the pace of CD4þ and CD8þ T cell recon-
stitution in both the ABA and StdRx cohorts. As shown in
Figure 5A and B, the StdRx patients demonstrated statisti-
cally signiﬁcantly higher total CD4þ counts (373 versus 159
cells/mL; P < .05, Wilcoxon rank-sum test), and non-
estatistically signiﬁcantly higher CD8þ counts (337 versus
159 cells/mL; P ¼ .08, Wilcoxon rank-sum test) at day þ28
post-HCT. However, by day þ100, reconstitution of total
numbers of CD4þ and CD8þ T cells was comparable in the 2
groups (Figure 5A and B). Day þ100 CD4 T cell reconstitution
in patients receiving abatacept was also similar compared
with the larger cohort of 22 contemporaneous controls
described above (mean day þ100 CD4þ T cell counts,
285  105 cells/mL for ABA patients and 282  44 cells/mL for
the 22 contemporaneous controls; p ¼ not signiﬁcant)
(Figure 5C). Furthermore, ABA patients had similar day þ100
and day þ365 CD4þ, CD8þ, and NK cell counts compared
with a previously published cohort of patients receiving T
cellereplete URD HCT for chronic myelogenous leukemia
[32], suggesting that abatacept as dosed in this study did not
induce a long-lasting defect in immune reconstitution. The
comparable long-term reconstitution of CD4þ T cells after
day þ100 in patients receiving abatacept is particularlynotable, given the pharmacodynamic effect of this drug on
early CD4þ proliferation (Figure 3B and C).
The decrease in CD4þ T cell numbers observed in ABA
versus StdRx patients early after transplantation correlated
predominantly with a corresponding reduction in the
percentage (representative example shown in Figure 6A) and
the absolute number of proliferating CD4þ T cells and CD4þ T
Figure 4. Longitudinal analysis of immune reconstitution in the ABA and StdRx cohorts. Shown are absolute numbers  SEM of cells from ABA patients (n ¼ 10; red
traces) and StdRx patients (n ¼ 6; black traces) measured longitudinally post-transplantation. Also shown is the mean  SEM of 10 healthy controls (green). (A)
Longitudinal analysis of the absolute lymphocyte count post-transplantation. (B) Longitudinal analysis of the absolute NK cell count (CD3/CD20/CD16þ/CD56þ/
lymphocytes) post-transplantation. (C) Longitudinal analysis of the absolute T cell count (CD3þ/CD20 lymphocytes) post-transplantation. (D) Relative proportion of T
cells (circles with solid lines) and NK cells (squares with dotted lines) post-transplantation in ABA patients (red traces) and StdRx patients (black traces). Also shown
is the mean  SEM of 10 healthy controls (green).
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expression (Figure 6B-F). The decrease in early proliferation
was observed both in unfractionated CD4þ T cells (Figure 6B)
and in the Tem and Tcm subsets (Figure 6D and E). Thus,
whereas the number of proliferating CD4þ Tn (Figure 6C) and
Temra cells (Figure 6F) were small, and not signiﬁcantly
different between the 2 cohorts, there were signiﬁcantly
fewer proliferating CD4þ Tcm and Tem at days þ14 and þ28
post-HCT in the ABA cohort compared with the StdRx cohort
(Figure 6D and E). As shown in these Figures (Figure 6B-F),
this difference in the number of proliferating CD4þ T cells
was conﬁned to early time points post-HCT, with similar
numbers of proliferating cells after day þ60. Consistent with
a more pronounced pharmacodynamic effect of abatacept on
CD4þ T cells versus CD8þ T cells, whereas there was a quan-
titative decrease in proliferating CD8þ Tem (64  38 versus
37  27 cells/mL) at day þ28 in the ABA cohort compared
with the StdRx cohort, this did not reach statistical signiﬁ-
cance for any CD8þ subset (data not shown). The decreased
CD4þ proliferation in ABA patients correlated with a corre-
sponding decrease in the number of CD4þ Tem cells early
after transplantation (Figure 6I). The difference in CD4þ Tcm
cells was less pronounced than that for Tem cells (Figure 6H).
This may be related in part to the fact that proliferating
central memory T cells have been shown to lose expressionof CCR7 and take on a T-effector/effector memory phenotype
[33,34]. Similar to what was observed for the number of
proliferating CD4þ Tn and Temra cell subsets (Figure 6C and
F), the reconstitution of CD4þ Tn and Temra cell subsets after
HCT was similar in the ABA and StdRx cohorts (Figure 6G and
J).
As shown in the representative example in Figure 6A, and
in longitudinal analysis in Figure 6K and L, the early decrease
in CD4þ proliferation in ABA patients was accompanied by
a decrease in HLA-DRþ/CD38þ-activated Tem and Tcm cells.
The representative example in Figure 6A shows the decrease
in the percentage of total CD4þ Tem cells that were activated
in ABA cohort compared with the StdRx cohort. The longi-
tudinal analysis shown in Figure 6K and L compares the
absolute numbers of activated cells in the 2 cohorts during
immune reconstitution. Just as with proliferation, this
differential effect of abatacept on CD4þ T cell activation was
transient, with similar numbers of activated Tcells later post-
HCT in the ABA and StdRX cohorts. As we observed for
proliferation in the CD4 Tn and Temra cells subpopulations
(Figure 6C and F), there was no difference in the number of
activated HLA-DRþ/CD38þ Tn and Temra cells in the ABA
cohort compared with the StdRx cohort (data not shown).
In addition to determining the number of proliferating
and activated CD4þ naïve and memory subsets in the ABA
Figure 5. Reconstitution of CD4þ and CD8þ T cells post-transplantation. (A and B) Longitudinal analysis of CD4þ and CD8þ T cell reconstitution in ABA and StdRx
cohorts. Shown are absolute numbers  SEM of cells from ABA patients (n ¼ 10, red traces) and StdRx (n ¼ 6, black traces) measured longitudinally post-
transplantation. Also shown is the mean  SEM of 10 healthy controls (green diamonds). *P < .05, Wilcoxon rank-sum test. (C) Comparison of day þ100 CD4þ T
cell counts between ABA patients (n ¼ 10) and the contemporaneous control cohort (n ¼ 22).
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CD127low/FoxP3þ putative Treg cells were enumerated as
well (ﬂow cytometry gating strategy shown in Figure 6M). As
shown in Figure 6N, early after transplantation, there was
a decrease in the number of these cells in the ABA cohort
compared with the StdRx cohort that reﬂected a corre-
sponding decrease in the proportion of CD4þ T cells that
were FoxP3þ in the ABA cohort (not shown). Whether this
early decrease in CD4þ/CD25high/CD127low/FoxP3þ cells
represents a bona ﬁde difference in functional regulatory
cells, or is a reﬂection of the fact that FoxP3 can also mark
proliferating and activated CD4þ T cells (especially in the
setting of lymphopenia-associated reconstitution) [35]
cannot be discerned from the phenotypic analysis per-
formed on this patient cohort, andwould require puriﬁcation
and functional analysis of large numbers of FoxP3 cells in the
2 cohorts, which was not feasible in this study. As with the
differential accumulation of proliferating and activated CD4þ
T cells in ABA and StdRx cohorts, the early differences in the
number of FoxP3þ cells in the 2 cohorts was transient, with
the numbers of FoxP3þ CD4þ similar in the ABA and StdRx
patients by day þ100 post-HCT.
DISCUSSION
Given the high morbidity and mortality of GVHD, new,
targeted approaches to immunosuppression remain a critical
unmet need, especially in the setting of URD and HLA-
mismatched transplantation. To address this, we conducted
a ﬁrst-in-disease trial of in vivo CD28eCD80/86 T cell cos-
timulation blockade with abatacept, which was added to
standard-of-care cyclosporine/methotrexate-based immu-
noprophylaxis in patients undergoing URD HCT for high-risk
hematologic malignancies. Although never previously tested
in vivo in HCT patients, T cell costimulation blockaderepresents a strategy for immune modulation with growing
relevance for multiple clinical indications. There are now
several costimulation blockade agents that are FDA-
approved for use in autoimmunity (including abatacept)
[36,37] and for solid organ transplantation [28]. This trial
demonstrated the feasibility of using abatacept in vivo
during HCT; the drug was well tolerated, and patients did not
develop unexpected infectious complications. Furthermore,
both the peak abatacept levels and its half-life were similar
to what has been previously observed in both HCs and in
patients with RA, indicating that abatacept can be reliably
dosed in this new patient population. To rigorously deter-
mine the utility of the 4-dose induction regimen of abatacept
used in this study [28] (compared with 3 induction doses
within 30 days for patients with RA), and the correspond-
ingly higher trough levels observed in ABA patients
compared with RA patients, future clinical trials will be
necessary, with direct comparison of abatacept dose inten-
sity and, potentially, routes of administration (i.v. versus s.c.).
In this study, we determined the pharmacodynamic effect
of abatacept in HCT by monitoring its impact on T cell
proliferation and activation. We found that the ABA patients
accumulated signiﬁcantly fewer proliferating (Ki-67þ) and
activated (HLA-DRþ/CD38þ) CD4þ T cells early after trans-
plantation compared with the StdRx cohort. Consistent with
the improved CD4þ T cell proliferation/activation proﬁle,
patients treated with abatacept demonstrated a low rate of
early aGVHD. Thus, despite the fact that all patients enrolled
on this trial received URD HCT, and 6 patients received
transplantations from HLA-mismatched donors, there were
only 2 cases of grade II-IV aGVHD before dayþ100, and no use
of salvage therapies to treat steroid-refractory aGVHD.
Although the observation of only 2 disease recurrences (both
in patients with minimum residual disease) with 16-month
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increased risk of disease relapse, both the GVHD-related and
the relapse-related outcomes require evaluation in a larger
patient cohort. These larger studies will also be able to test
the hypothesis generated in the current study, that decreased
CD4þ T cell proliferation will correlate on a per-patient basis
with a lower risk of developing severe aGVHD.
Although only 2 of our 10 ABA patients developed grade II-
IV GVHD before day þ100 post-HCT, of potential importance
for future considerations in abatacept dosing, 1 additional
patient on the study developed steroid-responsive late
aGVHD, and 2 patients developed severe cGVHD. Given the
limited exposure to abatacept in this trial (with levels<50 mg/
mL by day þ60 and <15 mg/mL by day þ100), these late
manifestations of GVHD could indicate that extending the
abatacept dosing schedule may be beneﬁcial. Moreover,
although not tested in this trial, given the efﬁcacy of abatacept
in ameliorating chronic joint disease in RA [38,39] and the
anecdotal experience of improved joint and other connective
tissue features of cGVHD, the use of this agent asmaintenance
therapy may provide a nondepletional approach for cGVHD.
The more signiﬁcant impact of abatacept on CD4þ T cell
versus CD8þ T cell function suggests that other immuno-
suppressive pairings may be required to elicit a greater
impact on CD8þ function. Indeed, our group and others have
shown that pairing CD28-CD80/86 T cell blockade withA
Figure 6. Transient inhibition of accumulation of proliferating and activated CD4þ T
following gating strategy. Lymphocytes were gated, and then CD3þ/CD14 T cells wer
Tn (CD45RAþ/CCR7þ), Tcm (CD45RA/CCR7þ), Tem (CD45RA/CCR7), and Temra (CD
The amount of proliferation (Ki-67 expression) or activation (dual HLA-DRþ/CD38
Longitudinal analysis of the number of proliferating (Ki-67þ) total CD4þ (B), CD4þ Tn
Shown are absolute numbers  SEM of cells from ABA patients (n ¼ 10, red traces) and
shown is the mean  SEM of cells from 10 healthy controls (green diamonds). (G-J) Lo
Tem (I), and CD4þ Temra (J) cells in the ABA and StdRx cohorts. Shown are absolute n
black traces) measured longitudinally post-transplantation. Also shown is the mean 
analysis of the total number of activated (HLA-DRþ/CD38þ) CD4þ Tem (K) and CD4þ Tc
cells from ABA patients (n ¼ 10, red traces) and StdRx (n ¼ 6, black traces) measured lo
10 healthy controls (green diamonds). (M) Representative ﬂow cytometry analysis of
identiﬁed. These cells were gated for CD127, CD25, and FoxP3. Putative Tregs are iden
of the total number of CD3þ/CD4þ/CD127low/CD25high/FoxP3þ cells in ABA and StdRx c
red traces) and StdRx (n ¼ 6, black traces) measured longitudinally post-transplanta
diamonds). *P < .05; **P < .01, Wilcoxon rank-sum test.either mechanistic target of rapamycin inhibition or CD40-
CD154 blockade can effectively control both CD4 and CD8
alloreactivity [21,40-42]. Thus, novel costimulation blockade
combinations, including adding abatacept to sirolimus-based
regimens as well as to other targeted therapies, represents an
important area for future investigation.
When considering the safety of adding abatacept to stan-
dard GVHD prophylaxis with cyclosporine þ methotrexate, it
is important to note that the reduced Tcell proliferation in our
patients on the ABA trial was transient and did not result in
long-term or wholesale T cell depletion. At later time points,
CD4þ T cell reconstitution was similar in the ABA and StdRx
cohorts. Although the lack of abatacept-induced T cell deple-
tion might have been responsible for the similarity in
day þ100 immune reconstitution in the 2 cohorts, this also
might have been inﬂuenced by the fact that 3 of 7 patients in
the StdRx cohort developed early severe aGVHD requiring
high-dose steroids as well as salvage therapy with inﬂiximab
(Supplemental Table S4). Two of these StdRx patients died of
GVHD before dayþ100 post-HCT (at daysþ46 andþ95). Both
the salvage therapy and the patient death in the StdRx cohort
might have inﬂuenced the subsequent group statistics for this
cohort.
Consistent with the lack of T cell depletion with abata-
cept, no patients in the ABA cohort displayed any overt signs
of T celledependent immune compromise. There wascell subsets in ABA patients. (A) Representative ﬂow cytometry showing the
e identiﬁed. CD4þ/CD8 and CD4/CD8þ populations were identiﬁed, and then
45RAþ/CCR7) subpopulations of both CD4þ and CD8þ T cells were identiﬁed.
þ expression) on each of these subpopulations was then determined. (B-F)
(C), Tcm (D), Tem (E), and Temra (F) subpopulations in ABA and StdRx cohorts.
StdRx (n ¼ 6, black traces) measured longitudinally post-transplantation. Also
ngitudinal analysis of the total number of reconstituting CD4þ Tn (G), Tcm (H),
umbers  SEM of cells from ABA patients (n ¼ 10, red traces) and StdRx (n ¼ 6,
SEM of cells from 10 healthy controls (green diamonds). (K and L) Longitudinal
m (L) cells in the ABA and StdRx cohorts. Shown are absolute numbers  SEM of
ngitudinally post-transplantation. Also shown is the mean  SEM of cells from
putative Tregs. Lymphocytes were identiﬁed, and then CD3þ/CD4þ T cells were
tiﬁed as CD3þ/CD4þ/CD127low/CD25high/FoxP3þ cells. (N) Longitudinal analysis
ohorts. Shown are absolute numbers  SEM of cells from ABA patients (n ¼ 10,
tion. Also shown is the mean  SEM of cells from 10 healthy controls (green
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antiviral immunity as measured by in vitro functional anal-
ysis. There were also no cases of adenoviremia, high-level
EBV viremia, malignant PTLD, or infection-related
mortality; however, 1 patient developed low-level EBV
reactivation, and 1 developed an EBV-encoded RNAepositive
polyclonal plasmacytic hyperplasia. Because we do not
routinely measure EBV reactivation in patients not receiving
T celledepleted transplantations at our institution, it is not
possible to make a direct comparison of the rate of EBV
reactivation in this cohort and a similar cohort not receiving
abatacept. This issue will be addressed directly in the
randomized Phase II trial of abatacept currently underway.
Of note, in the setting of abatacept-related inhibition of T cell
accumulation, there appeared to be a compensatory expan-
sion of NK cells in these patients (Figure 3D). The correlation
of this NK cell expansion with protection from infectious
disease (or GVHD) will be investigated in detail in the
ongoing Phase II trial of abatacept for GVHD prevention.
Because the use of HLA-disparate transplantation pairs for
HCT is increasing, recipients face the associated risks of early
exuberant T cell activation leading to severe disease. GVHD
occurring in the setting of HLA mismatch often begins at the
time of lymphocyte engraftment and can be extremely
difﬁcult to control, ultimately leading to high rates of early
TRM despite multimodal salvage therapies [1,2]. Consider-
able efforts have been made to develop a form of GVHD
prophylaxis that is more effective than the standard
approach of a calcineurin inhibitor and methotrexate.
Nonspeciﬁc donor T cell depletion, achieved using i.v. antie
T-cell globulin or ex vivo T cell depletion, has been shown to
provide potent protection against aGVHD; however,
randomized controlled trials have shown that this strategy
fails to improve survival [5,7,43], apparently owing in part to
higher rates of infection [5,7,43] and leukemic relapse [5].
The efﬁcacy of more speciﬁc inhibition of early alloprolifer-
ation to limit the mortality of early GVHD after HLA-
mismatched HCT is now increasingly supported by the
literature, with the promising results of post-transplantation
cyclophosphamide the most recent example of successfulapplication of inhibition of alloproliferation in HLA-
mismatched HCT [44]. The success of regimens targeting
alloproliferation will depend on the identiﬁcation of agents
that are able to pair with existing standard-of-care immu-
noprophylaxis to better control this early alloresponse,
especially in the setting of HLA mismatch, and to do so
without compromising control of infectious disease or
malignant relapse. The present trial demonstrates for the
ﬁrst time the potential of in vivo T cell costimulation
blockade to inhibit early T cell proliferation and activation,
and the feasibility of adding the costimulation blockade
agent abatacept to standard-of-care immunoprophylaxis.
The pharmacokinetic and pharmacodynamic effects of aba-
tacept suggest that further investigation of its efﬁcacy during
URD HCT in a larger randomized Phase II trial is warranted.ACKNOWLEDGMENTS
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